Delayed
Toronto S.E.
03:56:03 2023-03-07 pm EST
|
5-day change
|
1st Jan Change
|
0.005
CAD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: März |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
99.37
|
328.9
|
270.9
|
48.56
|
42.32
|
29.2
|
Enterprise Value (EV)
1 |
94.28
|
309.4
|
245.8
|
63.42
|
53.76
|
42.87
|
P/E ratio
|
-13.1
x
|
-19.7
x
|
-9.22
x
|
-1.27
x
|
-0.85
x
|
-1.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
339
x
|
722
x
|
1,265
x
|
2.64
x
|
17
x
|
8.06
x
|
EV / Revenue
|
321
x
|
679
x
|
1,148
x
|
3.45
x
|
21.6
x
|
11.8
x
|
EV / EBITDA
|
-26.2
x
|
-23.6
x
|
-9.18
x
|
-2.13
x
|
-2.74
x
|
-8.57
x
|
EV / FCF
|
-14.1
x
|
-86.7
x
|
-14.2
x
|
-4.08
x
|
-10.2
x
|
-124
x
|
FCF Yield
|
-7.11%
|
-1.15%
|
-7.05%
|
-24.5%
|
-9.79%
|
-0.8%
|
Price to Book
|
22.6
x
|
12.8
x
|
5.39
x
|
2.55
x
|
-18.8
x
|
-2.88
x
|
Nbr of stocks (in thousands)
|
150,558
|
223,738
|
265,551
|
277,486
|
384,746
|
530,868
|
Reference price
2 |
0.6600
|
1.470
|
1.020
|
0.1750
|
0.1100
|
0.0550
|
Announcement Date
|
7/26/17
|
7/24/18
|
7/8/19
|
9/14/20
|
10/1/21
|
9/30/22
|
Fiscal Period: März |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.2934
|
0.4558
|
0.2141
|
18.4
|
2.489
|
3.622
|
EBITDA
1 |
-3.598
|
-13.09
|
-26.77
|
-29.82
|
-19.61
|
-5.001
|
EBIT
1 |
-4.054
|
-13.63
|
-27.88
|
-31.61
|
-21.29
|
-6.454
|
Operating Margin
|
-1,381.43%
|
-2,990.46%
|
-13,024.89%
|
-171.78%
|
-855.38%
|
-178.2%
|
Earnings before Tax (EBT)
1 |
-4.316
|
-14.05
|
-27.86
|
-37.42
|
-42.27
|
-12.93
|
Net income
1 |
-4.316
|
-14.05
|
-27.86
|
-37.42
|
-42.27
|
-12.93
|
Net margin
|
-1,470.89%
|
-3,081.94%
|
-13,012.97%
|
-203.31%
|
-1,697.84%
|
-357.01%
|
EPS
2 |
-0.0503
|
-0.0745
|
-0.1106
|
-0.1375
|
-0.1299
|
-0.0286
|
Free Cash Flow
1 |
-6.701
|
-3.569
|
-17.33
|
-15.53
|
-5.263
|
-0.3446
|
FCF margin
|
-2,283.55%
|
-782.99%
|
-8,097.93%
|
-84.36%
|
-211.44%
|
-9.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/26/17
|
7/24/18
|
7/8/19
|
9/14/20
|
10/1/21
|
9/30/22
|
Fiscal Period: March |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
14.9
|
11.4
|
13.7
|
Net Cash position
1 |
5.09
|
19.5
|
25.1
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.4985
x
|
-0.5835
x
|
-2.734
x
|
Free Cash Flow
1 |
-6.7
|
-3.57
|
-17.3
|
-15.5
|
-5.26
|
-0.34
|
ROE (net income / shareholders' equity)
|
493%
|
-92.8%
|
-72.6%
|
-107%
|
-513%
|
204%
|
ROA (Net income/ Total Assets)
|
-24.9%
|
-37.8%
|
-38.3%
|
-33.2%
|
-30.5%
|
-14.1%
|
Assets
1 |
17.33
|
37.2
|
72.76
|
112.6
|
138.5
|
91.4
|
Book Value Per Share
2 |
0.0300
|
0.1200
|
0.1900
|
0.0700
|
-0.0100
|
-0.0200
|
Cash Flow per Share
2 |
0.0600
|
0.1000
|
0.1200
|
0
|
0
|
0
|
Capex
1 |
0.01
|
1.25
|
12.3
|
11.1
|
0.12
|
1.58
|
Capex / Sales
|
2.2%
|
274.82%
|
5,744.2%
|
60.13%
|
4.81%
|
43.58%
|
Announcement Date
|
7/26/17
|
7/24/18
|
7/8/19
|
9/14/20
|
10/1/21
|
9/30/22
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 1.98M | | +39.33% | 6.11B | | -18.38% | 4.35B | | -9.17% | 3.19B | | +3.98% | 3.15B | | -3.41% | 2.51B | | +48.74% | 1.98B | | -4.82% | 1.74B | | -1.24% | 1.63B | | -8.96% | 1.6B |
Alternative Medicine
|